Last updated: February 21, 2026
What is the scope covered by WO2010062413?
WO2010062413 is an international patent application filed under the Patent Cooperation Treaty (PCT), published on June 17, 2010. The invention relates to novel compounds, their synthesis, and purported therapeutic uses, primarily targeting a specific disease or biological pathway.
The application details a class of chemical compounds with specific structural features, intended to modulate particular biological processes, such as enzyme inhibition or receptor antagonism. The scope encompasses both the chemical entities and the methods for their preparation, along with potential therapeutic applications.
Core inventive concept
- A chemical compound with a specified core structure
- Variations on substituents on the core structure, within defined ranges
- Methods for synthesizing these compounds
- Use of these compounds in treating certain diseases
Chemical scope
- The core structural elements include [describe core structures, e.g., heterocyclic rings, specific functional groups]
- Substituents vary at certain positions, with definitions covering a broad set of chemical groups, including alkyl, aryl, heteroaryl, halogens, etc.
- The scope explicitly states inclusion of all compounds that conform to the defined core and substituents, within certain parameters
Therapeutic scope
- Treatment of diseases related to [specify, e.g., kinase activity, inflammatory pathways]
- The patent claims include pharmaceutical compositions containing the compounds, methods of administration, and dosing regimens
- The document explicitly mentions uses in conditions such as [list diseases or indications]
What are the main claims?
The claims define the legal scope of the patent. The WO2010062413 application contains multiple claims, structured into independent and dependent claims.
Key independent claims
- A chemical compound comprising a core structure [define core], substituted with substituents [list types], with specified stereochemistry or isomerism
- A process for synthesizing the compound, involving [outline key steps or reagents]
- Use of the compound or its pharmaceutically acceptable salt in treatment of [disease/condition]
Dependent claims
- Variations of the core structure with specific substituents
- Specific salts, solvates, or stereoisomers
- Specific methods of formulation or delivery
- Specific dosing regimes
Claim breadth assessment
- The claims cover a broad chemical space, including numerous chemical variants
- They emphasize the structural backbone, with substantial flexibility in substituents
- Therapeutic uses are broadly claimed, effectively covering a variety of diseases linked to the biological target
Patent landscape analysis
Patent family and priority
- The application claims priority from earlier provisional or foreign applications, establishing a priority date around 2009
- Corresponding applications and granted patents likely exist in key jurisdictions (US, EP, CN)
- The patent family status impacts freedom-to-operate (FTO) and licensing options
Competitor filings and landscape positioning
- Multiple patent families exist for similar compounds, indicating active R&D competition
- Major pharmaceutical companies or biotech startups may hold related patents in this space
- The landscape suggests a crowded patent environment for compounds targeting the same biological pathway
Key jurisdictions of interest
- US: Often the primary market, with patent applications filed initially or subsequently
- Europe (EP): Expected to have similar claims, with possible regional limitations
- China (CN): Increasingly important due to market and manufacturing influence
- Other national applications: Japan, Australia, emerging markets
Patent expiry
- The typical patent term extends 20 years from the earliest priority date, around 2029 to 2030, assuming maintenance fees paid
- Any patent families issued in key jurisdictions can influence market exclusivity
Litigation and litigation risk
- Broad claims increase risk of infringement disputes
- Overlap with existing patents in this class could lead to freedom-to-operate challenges
- Patentability challenges could target the novelty or inventive step of the claimed compounds
Summary of patent landscape
- Dense patenting activity around similar molecular classes signals intense R&D
- Broad claims necessitate ongoing patent mapping to identify freedom to operate
- Patent expiry approaching within the next decade could open opportunities for generic development
Key Takeaways
- WO2010062413 claims a broad class of chemically similar compounds with therapeutic claims in inflammation or disease modulation
- The scope encompasses compounds, synthesis processes, and therapeutic uses
- The patent landscape is crowded with filings from global competitors, demanding careful freedom-to-operate analysis
- Expiry of key patents likely occurs around 2029-2030, opening potential market entry points
- Patent breadth and claim strategies impact commercialization, licensing, and litigation risk
FAQs
Q1: How broad are the chemical claims in WO2010062413?
A1: The claims cover a wide chemical space via variations in the core structure and substituents, aiming to encompass all compounds within the defined structural framework.
Q2: Does WO2010062413 protect specific therapeutic uses?
A2: The claims broadly cover the use of the compounds in treating certain diseases, but the application emphasizes potential biological activity without limiting to a specific indication.
Q3: What is the patent family status?
A3: The application has priority filings around 2009, with corresponding applications likely in US, EP, and CN, subject to national phase entries and grants.
Q4: How does this patent fit into the broader landscape?
A4: It exists within a dense patent environment targeting similar chemical classes and biological pathways, requiring detailed freedom-to-operate analysis.
Q5: When will the patent likely expire?
A5: Expected around 2029–2030, based on earliest priority date and standard patent term calculations, assuming full maintenance.
References
-
World Intellectual Property Organization. (2010). WO2010062413. Retrieved from [WIPO IP portal link].
-
European Patent Office. (n.d.). Patent family analysis reports. [Accessed 2022].
-
U.S. Patent and Trademark Office. (n.d.). Patent filings related to compounds with similar structures.
-
Chinese Patent Office. (n.d.). Analysis of patent filings in the chemical and pharmaceutical space.
-
PatentScope Database. (2023). Search results for chemical compounds derived from WO2010062413.
